The overall goal of the Mitogenic Signaling Networks project is the development of high level statistical and specific physico-chemical models that describe key features of mitogenic signaling networks activated by ErbB receptors and by oncogenic K-ras. Over the past 4 years we have made significant progress in developing models of ErbB family mitogenic signaling networks in a variety of cell types, including statistical and kinetic models describing the effects of increased expression of various ErbB family members. Over the next five years we will extend these models to include mitogenic signaling networks resulting from mutant isoforms of EGFR and K-Ras that are directly associated with poor prognosis in human cancers of the central nervous and respiratory systems. Models will be developed and tested at a variety of scales, including in vitro cell culture systems, murine xenografts, and mouse cancer models. In addition, due to the success of a pilot project funded from our current ICBP, we will extend these models to integrate transcriptional regulatory networks, providing a more global, quantitative model of cellular regulation in response to oncogenic mutation. Since therapeutic resistance is one of the hallmarks of lung and brain tumors driven by mutant EGFR and mutant Ras, in the next phase of this project we will quantify and model signaling and transcriptional network alterations resulting from treatment with a variety of therapeutics, including classical chemotherapeutics, targeted therapeutics, and radiation. The goal of this project is to understand adaptation mechanisms used by tumor cells in developing therapeutic resistance in order to target these adaptive mechanisms to revert resistance. Quantitative models of mitogenic signaling network responses to therapeutics will be applied to human tumors to test their ability to predict responsiveness of human tumors to selected chemotherapeutic agents. This project will facilitate the integration of mitogenic signaling network models with DNA damage response models developed in Project 2, leading to more integrated models of cellular regulatory networks.
EGFR and Ras mutations are prevalent in brain and lung cancers and are correlated with poor patient prognosis. Current therapeutic options have not significantly extended survival rates. We propose to develop quantitative models describing signaling and transcriptional networks activated by these mutant isoforms. Models will be used to identify novel therapeutic targets and adaptive mechanisms associated with therapeutic resistance.
|Kulkarni, Madhura; Tan, Tuan Zea; Syed Sulaiman, Nurfarhanah Bte et al. (2018) RUNX1 and RUNX3 protect against YAP-mediated EMT, stem-ness and shorter survival outcomes in breast cancer. Oncotarget 9:14175-14192|
|Oudin, Madeleine J; Barbier, Lucie; Schäfer, Claudia et al. (2017) MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer. Mol Cancer Ther 16:143-155|
|Bruno, Peter M; Liu, Yunpeng; Park, Ga Young et al. (2017) A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat Med 23:461-471|
|Werbin, Jeffrey L; Avendaño, Maier S; Becker, Verena et al. (2017) Multiplexed Exchange-PAINT imaging reveals ligand-dependent EGFR and Met interactions in the plasma membrane. Sci Rep 7:12150|
|Miller, Miles A; Sullivan, Ryan J; Lauffenburger, Douglas A (2017) Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer. Clin Cancer Res 23:623-629|
|Nagel, Zachary D; Kitange, Gaspar J; Gupta, Shiv K et al. (2017) DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme. Cancer Res 77:198-206|
|White, Forest M; Wolf-Yadlin, Alejandro (2016) Methods for the Analysis of Protein Phosphorylation-Mediated Cellular Signaling Networks. Annu Rev Anal Chem (Palo Alto Calif) 9:295-315|
|Wilson, Jennifer L; Dalin, Simona; Gosline, Sara et al. (2016) Pathway-based network modeling finds hidden genes in shRNA screen for regulators of acute lymphoblastic leukemia. Integr Biol (Camb) 8:761-74|
|Zhao, Boyang; Hemann, Michael T; Lauffenburger, Douglas A (2016) Modeling Tumor Clonal Evolution for Drug Combinations Design. Trends Cancer 2:144-158|
|Tuncbag, Nurcan; Milani, Pamela; Pokorny, Jenny L et al. (2016) Network Modeling Identifies Patient-specific Pathways in Glioblastoma. Sci Rep 6:28668|
Showing the most recent 10 out of 222 publications